CHIR99021 - WNT pathway activator Inhibits GSK3, 10mg

793,35 zł brutto

645,00 zł netto


Związki drobnocząsteczkowe do badań nad komórkami macierzystymi. Nazwa: CHIR99021 Ścieżka/cel działania: WNT pathway activator; Inhibits GSK3 Aplikacja: Diabetes, Neural, CardiovascularWielkość opakowania: 10 mg Uwaga: minimalna wielkość zamówienia to 5 opakowań związków drobnocząsteczkowych. Zamówienie może obejmować różne produkty z tej kategorii.
Diabetes ResearchAs the prevalence of diabetes continues to rise, sustainable treatment options are a criticalnecessity. The transplantation of stem cell-derived beta cells presents a novel and long-termsolution for those suffering from type-I diabetes. A method to derive functional insulin-producing beta cells from hPSCs designed by Pagliuca, et al. (2014) presents a six-stage protocolusing a combination of multiple small molecules and growth factors (including CHIR99021,Retinoic Acid, SANT-1, LDN193189, Compound E, and RepSox) and has shown promise inameliorating hyperglycemia in mice.Neural ResearchWithin the complex realm of neurological diseases, neural stem cells and precursor cells haveincredible potential to not only replace injured or lost neurons, but also to act as deliveryvehicles for compounds to the brain. Qi, et al. (2017) describes a protocol in which a cocktail ofseven small molecules (including LDN193189, SB431542, XAV939, and CHIR99021) allow forthe creation of functional cortical neurons capable of producing long-range axonal projections.These cells begin to show mature neural characteristics in just 16 days, and later become fullyfunctional with electrophysiological properties and full network integration in-vivo. Cardiovascular ResearchAs the leading cause of death, globally, cardiovascular disease warrants an immense amountof research into potential treatment options. Stem cell-based therapies hold great promisein the possibility of regenerating functional cardiac tissue following myocardial infarction.Noor, et al. (2019) utilized cardiomyocyte differentiation protocols for hiPSCs created by Edri,et al. (2018) and Lian, et al. (2012) (incorporating small molecules such as IWP-2, IWP-4, andCHIR99021) for the creation of three-dimensional vascularized and perfusable heart patchesto ultimately be applied to personalized cardiac models.

No customer reviews for the moment.